Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 23-26

  Kristinsson, Sigurdur ^a   Koshiol, Jill ^b   Goldin, Lynn ^b   Björkholm, Magnus ^a   Turesson, Ingemar ^c   Gridley, Gloria ^b   McMaster, Mary ^b   Landgren, Ola ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune disease; Familial aggregation; Hepatitis C virus; Lymphoproliferative malignancy; Rheumatoid arthritis; Susceptibility; Waldenstr m

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; CHROMOSOME 3; CHROMOSOME 6; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; HEREDITY; HUMAN; IMMUNE SYSTEM; LYMPH FOLLICLE; MULTIPLE MYELOMA; PATHOGENESIS; SWEDEN; UNITED STATES; WALDENSTROEM MACROGLOBULINEMIA; CHRONIC LYMPHATIC LEUKEMIA; GENETICS; IMMUNOLOGY; REVIEW;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649519462     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.004     Document Type: Article

References (40)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-5.
2. Björkholm M. Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. In: Canellos G, Lister A, Young B, eds. The Lymphomas (2d ed). Philadelphia: W.B. Saunders, 2006:374-380.
3. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996-3001.
4. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82:1078-81.
5. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993; 82:3148-50.
6. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 2008; 112:3052-6.
7. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:1564-77.
8. Bjorkholm M, Johansson E, Papamichael D, et al. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study. Semin Oncol 2003; 30:226-30.
9. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759-64.
10. Massari R, Fine JM, Metais R. Waldenstrom's macroglobulinaemia observed in two brothers. Nature 1962; 196:176-8.
11. Fine JM, Lambin P, Massari M, et al. Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenstrom's macroglobulinemia. Acta Med Scand 1982; 211:237-9.
12. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia 1993; 7:1363-9.
13. McMaster ML, Goldin LR, Bai Y, et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 2006; 79:695-701.
14. Ogmundsdottir HM, Johannesson GM, Sveinsdottir S, et al. Familial macroglobulinaemia: hyperactive B-cells but normal natural killer function. Scand J Immunol 1994; 40:195-200.
15. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006; 17:488-94.
16. Goldin LR, Landgren O, McMaster ML, et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14:2402-6.
17. Goldin LR, Pfeiffer RM, Li X, et al. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004; 104:1850-4.
18. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100:1902-8.
19. Rudd MF, Sellick GS, Webb EL, et al. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006; 108:638-44.
20. Hohaus S, Massini G, D'Alo F, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003; 9:3435-40.
21. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92:960-9.
22. Lindblad K, Schalling M. Expanded repeat sequences and disease. Semin Neurol 1999; 19:289-99.
23. Vulliamy T, Marrone A, Szydlo R, et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004; 36:447-9.
24. Daugherty SE, Pfeiffer RM, Mellemkjaer L, et al. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14:1245-50.
25. Vieland VJ, Huang J. Statistical evaluation of age-at-onset anticipation: a new test and evaluation of its behavior in realistic applications. Am J Hum Genet 1998; 62:1212-27.
26. Aoki H, Takishita M, Kosaka M, et al. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995; 85:1913-9.
27. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994; 83:3647-53.
28. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297:2010-7.
29. Koshiol J, Gridley G, Engels EA, et al. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med 2008; 168:1903-9.
30. Goldin L, Landgren O. Autoimmunity and Lymphomagenesis. Int J Cancer 2009; 124:1497-502.
31. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003; 4:679-85.
32. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, based on November 2007 SEER data submission. Bethesda, MD: National Cancer Institute, 2008.
33. Konda A, Duffy MC. Surveillance of patients at increased risk of colon cancer: inflammatory bowel disease and other conditions. Gastroenterol Clin North Am 2008; 37:191-213, viii.
34. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985; 78:29-32.
35. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year propective study in France. Blood 2002; 99:3909-15.
36. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007; 8:2089-107.
37. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14:1943-9.
38. Usman AR, Yunus MB. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 1996; 23:1095-7.
39. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133:173-92.
40. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 2008; 35:1245-55.